In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma

Mariam M. AlHilli, Marc A. Becker, S. John Weroha, Karen S. Flatten, Rachel M. Hurley, Maria I. Harrell, Ann L. Oberg, Matt J. Maurer, Kieran M. Hawthorne, Xiaonan Hou, Sean C. Harrington, Sarah McKinstry, X. Wei Meng, Keith M. Wilcoxen, Kimberly R. Kalli, Elizabeth M. Swisher, Scott H. Kaufmann, Paul Haluska

Research output: Contribution to journalArticlepeer-review

35 Scopus citations


Objective Poly(ADP-ribose) polymerase (PARP) inhibitors have yielded encouraging responses in high-grade serous ovarian carcinomas (HGSOCs), but the optimal treatment setting remains unknown. We assessed the effect of niraparib on HGSOC patient-derived xenograft (PDX) models as well as the relationship between certain markers of homologous recombination (HR) status, including BRCA1/2 mutations and formation of RAD51 foci after DNA damage, and response of these PDXs to niraparib in vivo. Methods Massively parallel sequencing was performed on HGSOCs to identify mutations contributing to HR deficiency. HR pathway integrity was assessed using fluorescence microscopy-based RAD51 focus formation assays. Effects of niraparib (MK-4827) on treatment-naïve PDX tumor growth as monotherapy, in combination with carboplatin/paclitaxel, and as maintenance therapy were assessed by transabdominal ultrasound. Niraparib responses were correlated with changes in levels of poly(ADP-ribose), PARP1, and repair proteins by western blotting. Results Five PDX models were evaluated in vivo. Tumor regressions were induced by single-agent niraparib in one of two PDX models with deleterious BRCA2 mutations and in a PDX with RAD51C promoter methylation. Diminished formation of RAD51 foci failed to predict response, but Artemis loss was associated with resistance. Niraparib generally failed to enhance responses to carboplatin/paclitaxel chemotherapy, but maintenance niraparib therapy delayed progression in a BRCA2-deficient PDX. Conclusions Mutations in HR genes are neither necessary nor sufficient to predict response to niraparib. Assessment of repair status through multiple complementary assays is needed to guide PARP inhibitor therapy, design future clinical trials and identify ovarian cancer patients most likely to benefit from PARP inhibition.

Original languageEnglish (US)
Pages (from-to)379-388
Number of pages10
JournalGynecologic oncology
Issue number2
StatePublished - Nov 1 2016


  • BRCA
  • DNA repair
  • Homologous recombination
  • Niraparib
  • Ovarian cancer
  • PARP inhibitors
  • Xenografts

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology


Dive into the research topics of 'In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma'. Together they form a unique fingerprint.

Cite this